ArticleAnnals of clinical and translational neurology2026
Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNovel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration.
objectivesThis study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
methodsBased on the Third China National Stroke Registry (CNSR-III), we analyzed 14,476 participants aged ≥ 18 years with ischemic stroke or transient ischemic attack. Novel composite inflammatory markers were calculated, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune inflammation value (PIV). Outcomes at 1 year included stroke recurrence (primary outcome) and ischemic stroke, composite vascular events, mortality, and poor functional outcome (mRS 2-6) as secondary outcomes. Multivariable Cox or logistic regression analyses were performed to estimate the association of composite inflammatory markers with these outcomes. XGBoost, IDI, and NRI were utilized to evaluate predictive performance. Additionally, subgroup analyses and sensitivity tests were conducted to assess the robustness of the findings.
resultsThere were 1403 (9.7%), 1300 (9.0%), 1484 (10.3), 483 (3.3%) and 2865 (21.7%) patients with recurrent stroke, ischemic stroke, composite vascular events, mortality, and poor functional outcome within 1 year. SII, PIV, PLR, NLR, SIRI, and MLR were positively associated with stroke recurrence, with hazard ratios (95% CIs) of highest-quartile vs. lowest-quartile 1.39 (1.20, 1.61), 1.40 (1.21, 1.62), 1.16 (1.00, 1.34), 1.42 (1.22, 1.66), 1.38 (1.18, 1.61) and 1.18 (1.02, 1.37), respectively. A graded increase in stroke risk across quartiles was observed (Log-rank p < 0.05). All six markers were positively associated with ischemic stroke, composite vascular events, mortality, and poor functional outcome. SIRI demonstrated better predictive performance [IDI: 0.004 (0.002, 0.007); NRI: 0.082 (0.052, 0.107)] than the other five composite inflammatory markers for stroke recurrence. Among eight XGBoost models, the AUC increased from 0.598 (base) to 0.610 (adding NIHSS/mRS), and further to 0.624 with the addition of SIRI, which was the highest.
conclusionsNovel composite inflammatory markers were significantly associated with an increased risk of adverse outcomes in stroke patients. When accounting for the influence of inflammatory markers, SIRI demonstrated stronger predictive ability for stroke recurrence than the other markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.